Acurx Pharmaceuticals reported cash from operations of -$1.71M and free cash flow of -$1.71M for the quarter ended Jun 2026, down 2.4% year over year. This cash flow statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||
| Net Income | -4.12M | -2.82M | -2.78M | -2.15M | -2.25M | -1.99M | -1.58M | -1.68M | -2.25M | |||||||||||||||
| Share-based Compensation | 7.40M | 0.67M | 1.34M | 5.64M | 4.94M | 0.70M | 2.94M | 4.13M | 3.29M | 0.83M | 3.82M | 3.88M | 3.88M | 0.35M | 4.56M | 0.32M | 1.24M | 0.29M | 0.26M | 0.72M | ||||
| Cash from Operations | -2.64M | -1.50M | -1.88M | -1.99M | -2.18M | -1.50M | -1.93M | -1.58M | -2.09M | -4.20M | -3.06M | -2.88M | -2.19M | -2.25M | -2.05M | -1.67M | -1.88M | -1.18M | -1.41M | -1.71M | ||||
| Change in Working Capital | ||||||||||||||||||||||||
| Change in Receivables | -0.13M | 0.05M | 0.05M | -0.05M | -0.05M | 0.04M | 0.01M | 0.01M | 0.04M | |||||||||||||||
| Change in Accured Expenses | -1.21M | 0.13M | -0.21M | -0.16M | 0.71M | 0.88M | 0.01M | 0.95M | 0.20M | -0.18M | 0.07M | 0.04M | 0.17M | -0.08M | -0.34M | 0.10M | -0.12M | -0.05M | 0.11M | 0.31M | ||||
| Financing Activities | ||||||||||||||||||||||||
| Other financing activities | 2.22M | 0.21M | ||||||||||||||||||||||
| Change in Capital Stock | ||||||||||||||||||||||||
| Net Shares Issued and Repurchased | 2.36M | 2.36M | 0.08M | 0.11M | 0.47M | 0.00M | 0.52M | 0.83M | 0.00M | 0.90M | 0.68M | 0.03M | ||||||||||||
| Net Equity Issued and Repurchased | -1.00 | 1.60M | 2.80M | 3.13M | 0.85M | |||||||||||||||||||
| Misc. | ||||||||||||||||||||||||
| Cash from Financing Activities | -1.00 | 4.62M | 4.51M | 0.32M | 1.59M | 0.19M | 2.99M | 3.09M | 1.72M | 2.83M | 3.11M | 3.11M | ||||||||||||
| Change in Cash | -2.64M | -1.50M | -1.88M | -1.99M | 1.52M | -1.50M | -1.93M | 1.97M | -2.09M | 0.42M | 1.45M | -2.56M | -0.60M | -2.06M | 0.94M | 1.42M | -0.16M | 1.65M | 1.70M | 1.40M | ||||
| Free Cash Flow | -2.64M | -1.50M | -1.88M | -1.99M | -2.18M | -1.50M | -1.93M | -1.58M | -2.09M | -4.20M | -3.06M | -2.88M | -2.19M | -2.25M | -2.05M | -1.67M | -1.88M | -1.18M | -1.41M | -1.71M | ||||
| Net Cash Flow | -2.64M | -1.50M | -1.88M | -1.99M | -2.18M | -1.50M | -1.93M | -1.58M | -2.09M | 0.42M | 1.45M | -2.56M | -0.60M | -2.06M | 0.94M | 1.42M | -0.16M | 1.65M | 1.70M | 1.40M |